BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:The bispecific and multispecific antibody field is advancing r
 apidly\, fuelled by strong clinical readouts\, growing biopharma investme
 nt\, and increasingly sophisticated antibody designs. As programs evolve 
 beyond first-generation bispecifics toward trispecific and multispecific 
 strategies\, the industry is sharpening its focus on improving efficacy w
 hile expanding the therapeutic window through improved safety and toxicit
 y profiles.\n\nWith an increasing number of bispecifics progressing towar
 d the clinic\, the inaugural World Bispecific Summit Europe brings Europe
 's bispecific leaders together for the first time\, building on the prove
 n success of the World Bispecific Summit US.\n\nThis industry-led forum d
 elivers deep technical discussions and case studies spanning novel antibo
 dy formats\, next-generation TCEs\, and bispecific ADCs\, accelerating bi
 specifics from bench to clinic through conditional activation strategies\
 , co-stimulation\, and translational insights.\n\nWith clinical momentum 
 accelerating and unresolved challenges still to solve\, now is the time t
 o connect\, collaborate\, and shape the future of bispecific therapies. J
 oin a high-calibre community in London\, July 2026\, and be part of the n
 ext wave of precision-driven care.\n\nURLs:Website: https://go.evvnt.com/
 3495668-0?pid=185Tickets: https://go.evvnt.com/3495668-2?pid=185Brochure:
  https://go.evvnt.com/3495668-3?pid=185\n\nPrices:Conference Only - Servi
 ce Provider: GBP 3199.00\,Conference + Workshop Day - Service Provider: G
 BP 4497.00\,Conference Day Only - Academic Pricing: GBP 2299.00\,Conferen
 ce + Workshop Day - Academic Pricing: GBP 3197.00\,Conference Only &nbsp\
 ;- Drug Developer: GBP 2699.00\,Conference + Workshop Day - Drug Develope
 r: GBP 3797.00\n\nSpeakers: David Cole\, Head of Research\, Accession The
 rapeutics\, Asis Palazon\, Chief Executive Officer\, Adaptam Therapeutics
 \, Petra Lutterbuese\, Principal Scientist\, Amgen\, Catherine Huntington
 \, Associate Director\, AstraZeneca\, Christopher Lloyd\, Director\, Biol
 ogics Engineering\, AstraZeneca\, Simon Plyte\, Chief Scientific Officer\
 , Biomunex Pharmaceuticals\, James Legg\, Chief Scientific Officer\, Cyto
 spire Therapeutics Ltd\, Tobias Schmidt\, Senior Vice President\, Head of
  Discovery\, DISCO Pharmaceuticals\, Arnaud Goepfert\, Vice President\, B
 iologics Engineering\, Ennovate Pharma\, Kristel Kemper\, Director\, Team
  Lead Early Translational Medicine and Research Projects\, Genmab\, Annel
 ise Vuidepot\, Chief Science and Technology Officer\, Immunocore\, Angus 
 Sinclair\, Chief Scientific Officer\, LabGenius Therapeutics\, Vanessa Bu
 atois\, Discovery Program Leader\, Light Chain Bioscience / Novimmune\, M
 artin Steegmaier\, Chief Scientific Officer\, Molecular Partners AG\, Dav
 id Granger\, Vice President\, Research and Development\, NovalGen\, Matth
 ew Lambert\, Senior Director\, Pfizer\, Abdullah Elsayed\, Group Leader\,
  R and D\, Philochem\, Andreas Hollenstein\, Senior Principal Scientist\,
  Immunosafety\, Roche\, Ercole Rao\, Group Leader\, Large Molecules Resea
 rch - Engineered Protein Therapies\, Sanofi\, Sarah Leonard\, Vice Presid
 ent\, Pre-Clinical Development\, T-Cypher Bio\, Harald Kolmar\, Head of D
 epartment Applied Biochemistry\, Technical University of Darmstadt\, Shir
 ley Peters\, Director of Antibody Engineering\, UCB\, Arne Scheu\, Co-Fou
 nder and CEO\, Valink Therapeutics\, Paul Moore\, Chief Scientific Office
 r\, Zymeworks\n\nCategory: Conferences | Science\, Health and Medicine | 
 Oncology\n\nDate and Time: 7th July 2026 at 8:00 am to 9th July 2026 at 4
 :00 pm\n\nVenue details: Novotel London West\, 1 Shortlands Hammersmith I
 nternational Ctre\, London\, England\, W6 8DR\, United Kingdom\n
DTEND:20260709T160000
DTSTAMP:20260512T223121Z
DTSTART:20260707T080000
LOCATION:Novotel London West\, 1\, Shortlands Hammersmith International Ct
 re\, London\, England\, W6 8DR\,
SEQUENCE:0
SUMMARY:The bispecific and multispecific antibody field is advancing rapid
 ly\, fuelled by strong clinical readouts\, growing biopharma investment\,
  and increa...
UID:0d74f9d7-01e3-41a5-980e-c140516464fe
END:VEVENT
END:VCALENDAR